This study highlights distinct molecular characteristics of RCC in patients with CKD and post-kidney transplant, identifying key mutations such as SDHA, BRD4, and DDR-related genes CHEK2 and BRCA2. These mutations suggest a complex interplay between renal dysfunction, tumorigenesis, inflammation, and immune modulation. Here, BRD4 is linked to renal cell carcinoma.